We serve Chemical Name:5-Fluoropyrimidine-4,6-diol CAS:106615-61-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:5-Fluoropyrimidine-4,6-diol
CAS.NO:106615-61-6
Synonyms:4,6-Pyrimidinediol, 5-fluoro-;5-Fluoro-6-hydroxy-4(1H)-pyrimidinone;5-Fluoropyrimidine-4,6-diol;5-Fluoro-pyrimidine-4,6-diol;4(3H)-pyrimidinone, 5-fluoro-6-hydroxy-;5-Fluoro-6-hydroxypyrimidin-4(3H)-one;5-fluoro-4-hydroxy-1H-pyrimidin-6-one
Molecular Formula:C4H3FN2O2
Molecular Weight:130.077
HS Code:2933599090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:295.4±35.0 °C at 760 mmHg
Density:1.7±0.1 g/cm3
Index of Refraction:1.596
PSA:66.24000
Exact Mass:130.017853
LogP:-1.24
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4,6-Pyrimidinediol, 5-fluoro- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-fluoro-4-hydroxy-1H-pyrimidin-6-one physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-Fluoropyrimidine-4,6-diol Use and application,5-Fluoro-6-hydroxypyrimidin-4(3H)-one technical grade,usp/ep/jp grade.
Related News: The FDA in announcing its approval noted that four, 12-week placebo-controlled clinical studies that included a total of 1,143 participants showed Nourianz offered a statistically significant decrease from baseline in daily “off” time compared to those on placebo. 2-(2,6-difluorophenyl)-1,4-dimethyl-5-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)-1,4,5,6-tetrahydropyrimidine manufacturers Over the duration of this study, investigators observed a 4.2% reduction in annualised absolute risk of cardiovascular death or heart failure hospitalisations compared to placebo. [1-(4-Bromo-benzyl)-1H-benzoimidazol-2-yl]-methyl-(1-phenethyl-piperidin-4-yl)-amine suppliers Specifically, the EC has cleared Verquvo (vericiguat) to treat patients who are stabilised after a recent decompensation event requiring intravenous therapy. Hydrazinecarbothioamide, N-[(3,4,5-trimethoxycyclohexyl)methyl]- vendor & factory.
